阿斯利康进博首日宣布追加1.36亿美元扩建青岛基地

Core Insights - AstraZeneca showcased its commitment to China at the 8th China International Import Expo, emphasizing its expanded production plans and sustainable development achievements [1] - The company signed a cooperation agreement to invest approximately $136 million to enhance production capacity in Qingdao, focusing on inhalation aerosol products for respiratory diseases [3] - AstraZeneca introduced two new oncology drugs approved in China, addressing the needs of nearly 3.8 million breast cancer patients [4] Group 1 - AstraZeneca has been a consistent participant in the Import Expo for eight consecutive years, highlighting its theme of "Honoring China's Commitment, Creating a Healthy Future" [1] - The Qingdao production facility expansion aims to better meet the treatment needs of asthma and COPD patients, utilizing energy-saving technologies for near-zero carbon operations [3] - The company’s global executive vice president expressed confidence in China's innovation ecosystem and the vision of advancing scientific progress and health [3] Group 2 - The three major production bases in China—Wuxi, Taizhou, and Qingdao—showcased significant progress in low-carbon transformation, with Wuxi achieving 100% renewable energy usage [3] - Taizhou's carbon emissions have been reduced by 97.5% compared to 2015 levels, while the Qingdao facility is expected to achieve near-zero carbon operations upon completion [3] - AstraZeneca's new oncology drugs, including Capecitabine and Dazatuzumab, will enhance treatment options for breast cancer patients in China [4] Group 3 - AstraZeneca has aligned its efforts with the "Healthy China 2030" initiative, introducing 18 innovative treatments over the past seven years across various disease areas [4] - The newly opened global strategic R&D center in Beijing is part of a $2.5 billion investment plan, aimed at accelerating the transformation of innovative results into life-changing medications [4]